Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3
Health Catalyst
Health Catalyst HCAT | 0.00 |
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:
HCAT) with a Buy and raises the price target from $2 to $3.